News and Reports
MLex Market Insight: How Celgene Uses Safety Concerns to Keep Its $7 Billion Cancer Drug on Top
January 12 Leah Nylen Pam Holt, a retired teacher in Grainger, Indiana, was diagnosed with cancer in 2014. At the time, her treatment — with a derivative of the once-banned sedative thalidomide — cost $588 a month. In the past few months, her share of the bill has risen to $640 a month. “I do […]